Hims & Hers Expands into Europe with ZAVA Acquisition
In the upcoming quarters, Hims & Hers plans to establish its own branded presence in European markets by using ZAVA's robust platform. ZAVA currently serves over 1.3 million active customers and conducted ~2.3 million consultations in 2024 across the UK, Germany, France, and Ireland.
A nurse in a telehealth platform talking with a patient on video call for consultation.
Hims & Hers intends to introduce a new dimension of personalized digital health in Europe and offer tailored care across dermatology, weight loss, sexual health, and mental health. The expansion will include access to British, German, and French healthcare providers who will deliver services in local languages to ensure a localized experience. While specific offerings and their rollout will be announced in the coming months, the deal is expected to commence by 2026.
Hims & Hers Health Inc. (NYSE:HIMS) is a telehealth platform that connects consumers to licensed healthcare professionals in the US, the UK, and internationally.
While we acknowledge the potential of HIMS as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the .
READ NEXT: and .
Disclosure: None. This article is originally published at Insider Monkey.
Sign in to access your portfolio
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
20 minutes ago
- Yahoo
Wall Street Piles Into London Mega Deal: Deutsche Bank Bets $1.7B on Olympia Revival
In a rare moment of optimism for UK commercial property, Deutsche Bank (NYSE:DB) is moving ahead with a 1.25 billion ($1.7 billion) refinancing of London's Olympia redevelopmenta deal that could end up being one of the largest real estate loans ever seen in Britain. The five-year loan, arranged by JPMorgan and Evercore, will replace the 875 million facility issued by a Goldman Sachs fund back in 2020. The project, steered by Deutsche Finance International and Yoo Capital, is approaching the final stretch of a 2.1 billion transformation, bringing 1.5 million square feet of hotels, exhibition space, and restaurants to West London. Warning! GuruFocus has detected 4 Warning Sign with DB. According to people familiar with the deal, more than 15 lenders competed to provide financingranging from investment banks to debt fundssuggesting a shift in sentiment that's worth paying attention to. While the loan hasn't officially closed, sources say it's priced above 500 basis points and expected to be finalized before the project's completion this fall. That level of demand for a single asset deal may hint at early signs of recovery in London's bruised commercial property sector, even as caution still dominates broader capital markets. The Olympia site was originally acquired in 2017 for 296 million. Seven years and billions of pounds later, it's being recast as a cultural anchor for West London. For Deutsche Bank, this could be a well-timed betbacking the asset through to stabilization and possibly unlocking new long-term upside. The market may still be jittery, but this deal shows that, in the right pockets, capital is not just returningit's getting competitive. This article first appeared on GuruFocus. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
20 minutes ago
- Yahoo
Puma Shares Plunge 17% After Outlook Slashed on Tariff Impact
Puma (PMMAF, Financials) shares tumbled as much as 18% before finishing 17% lower on Friday after the firm warned that its profits will fall because of rising U.S. import tariffs and problems within the German sportswear business now thinks that full-year sales will drop by a low double-digit amount and that it will lose money in 2025. This is a big change from its earlier prediction of up to 525 million ($614 million) in Hoeld, who became CEO on July 1 to spearhead a turnaround, said, We need to take a hard look at ourselves. Hoeld said in a media teleconference that Puma didn't live up to its own goals and that weak brand momentum, problems with channel mix, and too much inventory were among said that second-quarter revenues declined 2% year over year, to 1.94 billion ($2.27 billion), which was less than analysts had expected, which was 2.06 billion. The adjusted operating profit went from a profit of 13.2 million to a loss of 13.2 million. The company also had one-time costs of 84.6 million connected to its attempts to minimize in North America fell by 9%, while sales in Europe and Asia-Pacific also fell, which caused the said it sent more shipments to the U.S. ahead of projected tariff hikes, which caused its inventory levels to rise. Even though the company plans to raise prices in the fourth quarter, it thinks tariffs will cost them 80 million in gross profit in said at the beginning of this year that it would wait for bigger American brands to raise prices in the American market. "We don't want to be the leader," CFO Markus Neubrand stated in May. This article first appeared on GuruFocus. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
New York Times
22 minutes ago
- New York Times
Kennedy Intends to Overhaul Federal Compensation for Vaccine Injuries
Health Secretary Robert F. Kennedy Jr. on Monday announced a plan to shake up the nation's compensation system for people harmed by vaccines. The federal system, the Vaccine Injury Compensation Program, 'is broken, and I intend to fix it,' Mr. Kennedy wrote on X. 'I will not allow the V.I.C.P. to continue to ignore its mandate and fail its mission of quickly and fairly compensating vaccine-injured individuals.' The compensation program, created by Congress in 1986, allows people who believe they were injured by vaccines to apply for financial compensation. The system is operated by the Department of Health and Human Services, with federally appointed special masters serving as judges, and funded by a 75-cent surcharge on vaccines. Mr. Kennedy said he was working with Attorney General Pam Bondi on the effort to remake the system but did not provide details. Mr. Kennedy noted that the compensation program protects vaccine makers from liability in courts. He said that the compensation fund has paid out $5.4 billion to 12,000 petitioners, but argued that it 'no longer functions to achieve its Congressional intent.' The program is inefficient and corrupt, Mr. Kennedy said in his lengthy online post, and he charged that judges were prioritizing 'the solvency of the H.H.S. Trust Fund, over their duty to compensate victims.' Want all of The Times? Subscribe.
